ArticleTherapeutic advances in medical oncology2026
TensorFlow-based MobileNetV2 U-Net tumor segmentation and multiparametric MRI radiomics for predicting cervical lymph node metastasis in oral tongue squamous cell carcinoma.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In oral tongue squamous cell carcinoma (OTSCC) patients, cervical lymph node metastasis profoundly influences prognoses and is central to guiding surgical strategies. Mapping the likelihood of lymph node metastasis across different cervical nodal levels is essential for achieving precise surgical planning. Purpose: OTSCC is a prevalent head and neck malignancy. Accurate MRI-based tumor segmentation and prognostic prediction are essential for detecting lymph node metastasis and improving patient survival rates. However, the potential of deep learning techniques has been underexplored in this context. Design: This retrospective pilot study included 136 OTSCC patients with non-lymph node metastasis and lymph node metastasis who underwent primary and cervical lymph node dissection following baseline MRI. The development of a machine learning approach, incorporating an automatically segmented approach, enables the creation of a model capable of predicting cervical lymph node metastasis based on primary site tumors. Methods: We propose a two-stage OTSCC diagnostic workflow. First, a multiparametric fusion network (MobileNetV2 U-Net) was implemented using TensorFlow to integrate features from contrast-enhanced T1-weighted (CE-T1WI), T2-weighted (T2WI), and T1-weighted (T1WI) MRI sequences and automatically segment primary tumors. Next, radiomic models were constructed to predict cervical lymph node metastasis from these automated segmentations. A fusion nomogram combining radiomic features and clinical data was developed to predict metastasis status. For comparison, a radiomics model using manually segmented CE-T1WIs was also evaluated. Results: Data from 136 patients (mean age 50.29 ± 12.25 years; 100 men, 36 women) showed that the MobileNetV2 U-Net achieved a Dice similarity coefficient (DSC) of 85% and a mean intersection over union (IoU) of 76% on the training set, and a DSC 87% and an IoU 79% on the independent test set. The fusion nomogram achieved areas under the ROC curves of 0.98 and 0.93 on the training and test sets, respectively, when using the automated segmentation masks. The automated segmentation nomogram performed comparably to the model using manual segmentations for predicting lymph node metastasis. Conclusion: Our TensorFlow-based MobileNetV2 U-Net provides clinicians with an automated tool to delineate OTSCC tumors and predict cervical lymph node metastasis, potentially aiding personalized surgical planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.